Results 131 to 140 of about 26,645,245 (287)

Anatomical Description of the Main Gyri and Sulci of the Telencephalon of Alouatta belzebul. [PDF]

Anat Histol Embryol
Pereira DKS, de Melo FR, de Melo FCSA, Pereira KF, Vulcani VAS.   +4 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

P732: Identification of pathogenic expansions within FXN in individuals with suspected Friedreich ataxia diagnoses

Genetics in Medicine Open
Kaitlynne Bohm, Erin Sybouts, Carmen Noller, Ben Sullivan, Erik Strandberg, Luke Drury, Jim McKay, Rachel Clark   +7 more
doaj   +1 more source

A first-in-human Phase 1/1b randomized trial evaluating the safety and immunogenicity of a respiratory syncytial virus (RSV) virus-like particle subunit vaccine (IVX-121) in healthy young and older adults. [PDF]

Hum Vaccin Immunother
De Coster I, Leroux-Roels I, Withanage K, Suykens L, D'Onofrio V, Leroux-Roels G, van Damme P, Ciarlet M, Adams EM, Rida W, Wen J, MacDonald M, Price J, Kanesa-Thasan N.   +13 more
europepmc   +1 more source

Part-Land, Part-Water [PDF]

Landscape Architecture Frontiers, 2019
openaire   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

P639: Excavator: Removing the noise in exome analysis using machine learning

Genetics in Medicine Open
Brett Deml, Lexie Lobo, Becky Milewski, Benjamin Bluhm, Luke Drury   +4 more
doaj   +1 more source

Safety and efficacy of zuranolone in Japanese adults with major depressive disorder: An open-label, repeated-treatment part of a Phase 3 clinical trial. [PDF]

PCN Rep
Kato M, Nakagome K, Baba T, Sonoyama T, Fukuju H, Shimizu R, Gomez JC, Motomiya T, Inoue T.   +8 more
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Front Matter Volume 3.1

Scottish Studies, 1959
[Editor]
doaj